Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
Silexion Therapeutics Corp (SLXN) Debt to Capital Ratio data is not available for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-3.55M |
|
-- |
|
-- |
|
$3.68M |
|
$-3.68M |
|
$0.13M |
|
$-3.55M |
|
$-3.55M |
|
$-3.55M |
|
$-3.55M |
|
$-3.55M |
|
$-3.55M |
|
$-3.68M |
|
$-3.68M |
|
0.69M |
|
0.69M |
|
$-5.17 |
|
$-5.17 |
|
| Balance Sheet Financials | |
$3.74M |
|
$0.02M |
|
$0.51M |
|
$4.25M |
|
$3.98M |
|
-- |
|
$0.23M |
|
$4.20M |
|
$0.04M |
|
$0.04M |
|
$0.04M |
|
1.18M |
|
| Cash Flow Statement Financials | |
$-6.57M |
|
$-0.00M |
|
$2.82M |
|
$6.08M |
|
$2.32M |
|
$-3.75M |
|
$0.54M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.94 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
-- |
22.39 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.57M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8070.69% |
|
-8070.52% |
|
-83.63% |
|
-8070.45% |
|
$0.04 |
|
$-9.56 |
|
$-9.56 |
|